Orexo launches deprexis® and vorvida® in the US and provides updated financial guidance
· FDA´s “Enforcement Policy” and Orexo´s strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies · Preliminary estimated sales potential of USD 420-650 million for the DTx portfolio five years post launch · To enable accelerated launch of all three products investments will increase and OPEX for FY 2020 is expected to be in the range of SEK 750-800 million, from SEK 550-600 million Uppsala, Sweden – July 2, 2020 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces today the US launch of the scientifically